Dutasteride (Avodart) Provides No Clinical Benefit to Men with Recurrent Castrate Resistant Prostate Cancer

At the University of New Mexico School of Medicine in Albuquerque, New Mexico (SKS) the Department of Urology just completed a study that showed that dutasteride, the generic name for a dual 5alpha-reductase inhibitor made by GlaxoSmithKline and marketed under the name Avodartā„¢ in the US and Avolveā„¢ in Europe, when administered to men with [...]

Early Versus Deferred Androgen Suppression in the Treatment of Advanced Prostatic Cancer – Which Is Better?

An informative and comprehensive analysis of existing research studies evaluating the merits of early vs. deferred commencement of hormone therapy in men with advanced prostate cancer was recently published. The analysis (Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic [...]

Radiation Plus Hormone Therapy Cuts Prostate Cancer Mortality by 50% in men with Locally Advanced Disease

Investigators have reported, at the American Society for Therapeutic Radiation and Oncology (ASTRO) 50th Annual Meeting, that when radiation is added to anti-androgen therapy (ADT), survival rates are increased by 50% in men receiving only ADT. "This randomized trial is the first to show that men with locally advanced prostate cancer will survive substantially longer [...]

Why ADT Ultimately Fails

Hair on a man's head offers clues about versatility of a molecule central to Advanced Prostate Cancer. Once again, those of us fighting advanced and recurrent prostate cancer are confronted with contradictory and confusing information. The usual first line treatment for advanced prostate cancer is hormone therapy (ADT). We all know that ADT is short [...]

Go to Top